Neurons expressing metabotropic glutamate receptor 5 (GRM5, also known as mGluR5) represent a critical component of the glutamatergic signaling system in the brain. GRM5 is a Group I metabotropic glutamate receptor that couples to Gq proteins and plays essential roles in synaptic plasticity, learning and memory, and neurological disease pathogenesis. This receptor is a major therapeutic target for neurological and psychiatric disorders.
GRM5-expressing neurons are widely distributed:
- Hippocampus: High expression in CA1-CA3 pyramidal neurons, dentate gyrus granule cells
- Cortex: Layers II-III and V, pyramidal neurons and interneurons
- Striatum: Medium spiny neurons, GABAergic projection neurons
- Basal ganglia: Substantia nigra pars reticulata, globus pallidus
- Thalamus: Intralaminar nuclei, relay nuclei
- Cerebellum: Purkinje cells, deep nuclei
- Brainstem: Various nuclei involved in motor control
GRM5 is an 118-kDa class C GPCR:
- Belongs to Group I mGluRs (mGluR1, mGluR5)
- Large extracellular venus fly trap domain for glutamate binding
- Distinct splice variants (mGluR5a, mGluR5b)
- Gq protein coupling activates PLCβ
- Generates IP3 and DAG second messengers
- Releases intracellular calcium from stores
- Forms homomers and heteromers with other mGluRs
- Interacts with Homer scaffolding proteins
- Regulates NMDA receptor function
- Modulates AMPA receptor trafficking
- Controls presynaptic release probability
- Generates slow excitatory postsynaptic potentials
- Critical for LTP and LTD induction
- Regulates dendritic spine morphology
- Controls actin cytoskeleton remodeling
- Mediates learning and memory
- Mobilizes intracellular calcium stores
- Activates calcium-dependent enzymes
- Regulates gene transcription
- Triggers structural plasticity
- Neuronal development and migration
- Axon guidance
- Neuroprotection (under certain conditions)
- Pain perception (peripheral and central)
- GRM5 dysfunction contributes to synaptic deficits
- Amyloid-beta interacts with mGluR5
- Altered expression in AD brains
- Target for cognitive enhancement
- GRM5 in basal ganglia motor circuits
- Modulates dopaminergic signaling
- Contributes to levodopa-induced dyskinesias
- Target for motor complications
- GRM5 hyperactivation contributes to excitotoxicity
- Mutant huntingtin alters mGluR5 signaling
- Target for neuroprotection
- Modulates striatal dysfunction
- GRM5 is a key therapeutic target
- Excessive mGluR5 signaling
- Negative allosteric modulators in clinical trials
- Improves synaptic function
- GRM5 antagonists show antidepressant effects
- Rapid-acting mechanisms
- Novel treatment target
- Modulates stress circuits
- Anxiogenic effects of GRM5 activation
- Anxiolytic effects of antagonists
- Target for anxiety disorders
- mGluR5 in pain transmission
- Peripheral and central mechanisms
- Target for analgesics
- Pro-convulsant effects of GRM5 activation
- Anticonvulsant potential of antagonists
- Target for anti-epileptic drugs
GRM5 is a clinically validated drug target:
- Mavoglurant (AFQ056): Clinical trials for Fragile X syndrome
- Basimglurant (RO4917523): Depression and anxiety trials
- Dipraglurant: Levodopa-induced dyskinesias
- CDPPB: Cognitive enhancement
- ADX47273: Investigational for schizophrenia
- Fragile X syndrome: mGluR5 NAMs improve symptoms
- Depression: Fast-acting antidepressants
- Levodopa-induced dyskinesias: Reduce dyskinesias
- Anxiety disorders: Anxiolytic potential
- [11C]ABP688: PET ligand for mGluR5
- Measures receptor availability
- Research and clinical applications
GRM5 serves as a biomarker:
- Genetic markers: GRM5 polymorphisms in disease
- Imaging: PET ligands for receptor density
- Expression: Postmortem brain studies
- Functional: Treatment response prediction
- mGluR5 in Alzheimer's disease (2021)
- GRM5 and Parkinson's disease dyskinesias (2020)
- mGluR5 negative modulators in Fragile X (2022)
- Metabotropic glutamate receptors in depression (2021)
- mGluR5 and synaptic plasticity (2019)
- GRM5 in Huntington's disease (2020)